List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8117068/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet, The, 2009, 373, 1532-1542.	6.3	546
2	Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients. Journal of the National Cancer Institute, 2006, 98, 708-714.	3.0	510
3	Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2007, 99, 706-714.	3.0	344
4	Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2008, 26, 132-149.	0.8	274
5	American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer. Journal of Clinical Oncology, 2010, 28, 4996-5010.	0.8	257
6	A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. European Journal of Epidemiology, 2020, 35, 49-60.	2.5	249
7	Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis. Journal of the National Cancer Institute, 2005, 97, 489-498.	3.0	235
8	American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood, 2010, 116, 4045-4059.	0.6	187
9	Erythropoietin or darbepoetin for patients with cancer. The Cochrane Library, 2012, 12, CD003407.	1.5	177
10	The erythropoietin receptor in normal and cancer tissues. Critical Reviews in Oncology/Hematology, 2008, 67, 39-61.	2.0	147
11	Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood, 2008, 111, 25-41.	0.6	130
12	Erythropoietin or Darbepoetin for patients with cancer. , 2006, , CD003407.		106
13	Cancer-related anemia and recombinant human erythropoietin—an updated overview. Nature Clinical Practice Oncology, 2006, 3, 152-164.	4.3	99
14	HIV-1–related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood, 2011, 117, 6100-6108.	0.6	99
15	Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. The Cochrane Library, 2009, , CD007303.	1.5	98
16	Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica, 2010, 95, 494-500.	1.7	93
17	Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. Antiviral Therapy, 2009, 14, 1065-1074.	0.6	92
18	Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood, 2009, 113, 5737-5742.	0.6	92

#	Article	IF	CITATIONS
19	Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. The Cochrane Library, 2008, , CD003189.	1.5	88
20	High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma – Results of a comprehensive meta-analysis. Cancer Treatment Reviews, 2007, 33, 338-346.	3.4	80
21	Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Advances, 2019, 3, 1197-1210.	2.5	76
22	Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Journal of Clinical Oncology, 2019, 37, 1336-1351.	0.8	73
23	HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis. International Journal of Cancer, 2016, 138, 45-54.	2.3	72
24	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Aids, 2009, 23, 2029-2037.	1.0	64
25	Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. Annals of Oncology, 2005, 16, 1381-1390.	0.6	63
26	Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. The Cochrane Library, 2010, 2010, CD003805.	1.5	62
27	HHV-8 seroprevalence: a global view. Systematic Reviews, 2014, 3, 11.	2.5	59
28	Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: A systematic review and meta-analysis. Cancer Treatment Reviews, 2006, 32, 377-389.	3.4	58
29	Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. , 2009, , CD007107.		58
30	High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. The Cochrane Library, 2011, 2011, CD004024.	1.5	57
31	Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. British Journal of Cancer, 2014, 111, 33-45.	2.9	54
32	Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. British Journal of Haematology, 2003, 122, 413-423.	1.2	51
33	Incidence Rate of Kaposi Sarcoma in HIV-Infected Patients on Antiretroviral Therapy in Southern Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 547-554.	0.9	51
34	Kaposi's Sarcoma in HIVâ€infected patients in South Africa: Multicohort study in the antiretroviral therapy era. International Journal of Cancer, 2014, 135, 2644-2652.	2.3	48
35	The burden of cancers associated with HIV in the South African public health sector, 2004–2014: a record linkage study. Infectious Agents and Cancer, 2019, 14, 12.	1.2	45
36	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	2.9	44

#	Article	IF	CITATIONS
37	Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. , 2011, , CD007110.		43
38	Twist and Shout: One Decade of Meta-Analyses of Erythropoiesis-Stimulating Agents in Cancer Patients. Acta Haematologica, 2011, 125, 55-67.	0.7	38
39	Incidence of AIDS-defining and Other Cancers in HIV-positive Children in South Africa. Pediatric Infectious Disease Journal, 2016, 35, e164-e170.	1.1	38
40	Cervical cancer risk in women living with HIV across four continents: A multicohort study. International Journal of Cancer, 2020, 146, 601-609.	2.3	37
41	Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Annals of Oncology, 2014. 25. 1709-1718.	0.6	34
42	ls human herpesvirus 8 infection more common in men than in women? Systematic review and metaâ€analysis. International Journal of Cancer, 2016, 139, 776-783.	2.3	27
43	Record linkage to correct underâ€ascertainment of cancers in HIV cohorts: The Sinikithemba HIV clinic linkage project. International Journal of Cancer, 2016, 139, 1209-1216.	2.3	25
44	Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. Clinical Infectious Diseases, 2016, 63, 1373-1379.	2.9	25
45	Pitfalls of practicing cancer epidemiology in resource-limited settings: the case of survival and loss to follow-up after a diagnosis of Kaposi's sarcoma in five countries across sub-Saharan Africa. BMC Cancer, 2016, 16, 65.	1.1	25
46	Cervical cancer risk and impact of Papâ€based screening in HIVâ€positive women on antiretroviral therapy in Johannesburg, South Africa. International Journal of Cancer, 2017, 141, 488-496.	2.3	23
47	An Insight Into Cervical Cancer Screening and Treatment Capacity in Sub Saharan Africa. Journal of Lower Genital Tract Disease, 2016, 20, 31-37.	0.9	21
48	HIV-associated malignancies in children. Current Opinion in HIV and AIDS, 2017, 12, 77-83.	1.5	21
49	Incidence and Treatment of Developmental Hip Dysplasia in Mongolia: A Prospective Cohort Study. PLoS ONE, 2013, 8, e79427.	1.1	21
50	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
51	Cancer in adolescents and young adults living with HIV. Current Opinion in HIV and AIDS, 2018, 13, 196-203.	1.5	16
52	Immunodeficiency and Cancer in 3.5 Million People Living With Human Immunodeficiency Virus (HIV): The South African HIV Cancer Match Study. Clinical Infectious Diseases, 2021, 73, e735-e744.	2.9	16
53	High Cancer Burden Among Antiretroviral Therapy Users in Malawi: A Record Linkage Study of Observational Human Immunodeficiency Virus Cohorts and Cancer Registry Data. Clinical Infectious Diseases, 2019, 69, 829-835.	2.9	15
54	Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation. The Cochrane Library, 2008, , CD004885.	1.5	13

#	Article	IF	CITATIONS
55	Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations. Leukemia and Lymphoma, 2011, 52, 444-457.	0.6	13
56	Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy. The Cochrane Library, 2015, , CD007107.	1.5	13
57	Health-Related Quality of Life of Young Adults Treated with Recombinant Human Growth Hormone during Childhood. PLoS ONE, 2015, 10, e0140944.	1.1	12
58	Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Advances, 2020, 4, 4029-4044.	2.5	12
59	Impact of Age and Socio-Economic Inequalities in Cancer Survival of Patients with Hodgkin's Lymphoma Diagnosed in England and Wales Blood, 2006, 108, 346-346.	0.6	12
60	Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis. Leukemia, 2008, 22, 1801-1803.	3.3	11
61	Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review. Critical Reviews in Oncology/Hematology, 2019, 136, 37-47.	2.0	11
62	Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa. BMC Cancer, 2017, 17, 611.	1.1	10
63	Does Combined Immunochemotherapy with the Monoclonal Antibody Rituximab Improve Overall Survival in the Treatment of Patients with Indolent Non-Hodgkin Lymphoma? Preliminary Results of a Comprehensive Meta-Analysis Blood, 2005, 106, 351-351.	0.6	10
64	Cancer risk in adolescents and young adults living with HIV in South Africa: a nationwide cohort study. Lancet HIV,the, 2021, 8, e614-e622.	2.1	9
65	Ten Years of Meta-analyses on Erythropoiesis-Stimulating Agents in Cancer Patients. Cancer Treatment and Research, 2010, 157, 217-238.	0.2	9
66	Cohort profile: the South African HIV Cancer Match (SAM) Study, a national population-based cohort. BMJ Open, 2022, 12, e053460.	0.8	9
67	Effectiveness of erythropoietin in the treatment of patients with malignancies: methods and preliminary results of a Cochrane review. Best Practice and Research in Clinical Haematology, 2005, 18, 449-454.	0.7	8
68	Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients. PLoS ONE, 2017, 12, e0189309.	1.1	8
69	High-Dose Chemotherapy with Autologous Stem Cell Support Is Not Superior to Conventional-Dose Chemotherapy in the First-Line Treatment of Aggressive Non-Hodgkin Lymphoma - Results of a Comprehensive Meta-Analysis Blood, 2004, 104, 920-920.	0.6	8
70	Treatment and outcome of AIDS-related Kaposi sarcoma in South Africa, Malawi and Zambia: an international comparison. Pan African Medical Journal, 2017, 28, 261.	0.3	7
71	Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Journal of Oncology Practice, 2019, 15, 399-402.	2.5	6
72	Fourth Biannual Report of the Cochrane Haematological Malignancies Group. Journal of the National Cancer Institute, 2006, 98, E1.	3.0	6

#	Article	IF	CITATIONS
73	Erythropoiesis-Stimulating Agents in the Treatment of Cancer-Associated Anemia. JAMA - Journal of the American Medical Association, 2008, 300, 2854.	3.8	6
74	Cervical Cancer Screening Cascade for women living with HIV: A cohort study from Zimbabwe. PLOS Global Public Health, 2022, 2, e0000156.	0.5	6
75	ls intravenous iron supplementation with erythropoiesis-stimulating agents beneficial in cancer patients with anemia?. Nature Clinical Practice Oncology, 2008, 5, 688-689.	4.3	5
76	Conjunctival cancer in people living with HIV. Current Opinion in Infectious Diseases, 2021, 34, 1-7.	1.3	5
77	Trends and Socio-Economic Inequalities in Cancer Survival of Patients with Hodgkin's Lymphoma Diagnosed in England and Wales between 1986 and 1999 Blood, 2005, 106, 749-749.	0.6	5
78	Cervical cancer in women living in South Africa: a record linkage study of the National Health Laboratory Service and the National Cancer Registry. Ecancermedicalscience, 2022, 16, 1348.	0.6	5
79	HHVâ€8 seroprevalence in HIVâ€positive and HIVâ€negative populations. International Journal of Cancer, 2015, 136, 1243-1243.	2.3	4
80	Fifth Biannual Report of the Cochrane Haematologic Malignancies Group—Focus on Multiple Myeloma. Journal of the National Cancer Institute, 2006, 98, E2.	3.0	4
81	Cancer in HIV-positive and HIV-negative adolescents and young adults in South Africa: a cross-sectional study. BMJ Open, 2021, 11, e043941.	0.8	4
82	Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group. Blood, 2008, 112, 4675-4675.	0.6	4
83	Screening test accuracy to improve detection of precancerous lesions of the cervix in women living with HIV: a study protocol. BMJ Open, 2020, 10, e037955.	0.8	4
84	Cancer incidence among people living with <scp>HIV</scp> in Zimbabwe: A record linkage study. Cancer Reports, 2022, 5, e1597.	0.6	4
85	Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: a systematic review and network meta-analysis. The Cochrane Library, 2022, 2022, .	1.5	4
86	Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group. Blood, 2008, 112, Iba-6-Iba-6.	0.6	3
87	Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents. Swiss Medical Weekly, 2013, 143, w13776.	0.8	3
88	Antibiotics plus granulocyte colony-stimulating factor reduces febrile neutropenia in the first cycle of chemotherapy in people with small-cell lung cancer. Cancer Treatment Reviews, 2006, 32, 234-238.	3.4	2
89	Epoetins and mortality in patients with cancer – Authors' reply. Lancet, The, 2009, 374, 287-288.	6.3	2
90	Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis. The Cochrane Library, 0, , .	1.5	2

#	Article	IF	CITATIONS
91	Combined Immunochemotherapy with Rituximab Improves Overall Survival in Patients with Follicular and Mantle Cell Lymphoma: Updated Meta-Analysis Results Blood, 2006, 108, 2760-2760.	0.6	2
92	Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myelogenous Leukemia: To Transplant or Not to Transplant? A Systematic Review of International Guidelines Blood, 2009, 114, 1419-1419.	0.6	2
93	Epoetin and Darbepoetin To Treat Cancer Patients: Updated Meta-Analysis Results Blood, 2005, 106, 751-751.	0.6	2
94	Title is missing!. Onkologe, 2001, 7, 1014-1021.	0.7	1
95	Screening test accuracy of portable devices that can be used to perform colposcopy for detecting CIN2+ in low- and middle-income countries: a systematic review and meta-analysis. BMC Women's Health, 2020, 20, 253.	0.8	1
96	Identification of Prognostic Factors in Early Unfavorable Stage Hodgkin's Lymphoma (HL): An Individual Patient Data Meta-Analysis Blood, 2006, 108, 2473-2473.	0.6	1
97	Preventing Infections in Cancer Patients: Antibiotics, Hematopoetic Growth Factors or Both? a Network Analysis. Blood, 2008, 112, 1315-1315.	0.6	1
98	Indicators and targets for cervical cancer prevention in countries with the highest HIV burden: A scoping review protocol. , 0, , .		1
99	Reply to El-Mllawanya et al. Clinical Infectious Diseases, 2017, 64, ciw880.	2.9	0
100	Hematopoietic Growth Factors Reduce Side Effects of Cancer Treatment: Results of Two Comprehensive Meta-Analyses Blood, 2004, 104, 5308-5308.	0.6	0
101	Second Biannual Report of the Cochrane Haematological Malignancies Group. Journal of the National Cancer Institute, 2005, 97, E1-E.	3.0	0
102	Third Biannual Report of the Cochrane Haematological Malignancies Group. Journal of the National Cancer Institute, 2005, 97, E2.	3.0	0
103	Identification of Prognostic Factors in Patients with Early Stage Unfavorable Hodgkin's Lymphoma: An Individual Patient Data Meta-Analysis Blood, 2005, 106, 5577-5577.	0.6	0
104	Impact of Combined Anti-Retroviral Therapy on HIV-Associated Non-Hodgkin-Lymphoma - a Prospective European Multi-Cohort Study on Behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Blood, 2008, 112, 878-878.	0.6	0
105	HIV-Related Hodgkin Lymphoma in the Era of Highly Active Antiretroviral Therapy: Incidence and Survival in a Prospective European Multi-Cohort Study On Behalf of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) Study Group Blood, 2009, 114, 895-895.	0.6	0
106	NHL risk in HIV+ adults on antiretroviral therapy in four continents Journal of Clinical Oncology, 2016, 34, 1578-1578.	0.8	0
107	I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes. Blood, 2019, 134, 4752-4752.	0.6	0